Recombinant Human Glial fibrillary acidic protein (GFAP), partial

^{In
Stock}

中文名稱：

人GFAP重組蛋白
貨號(hào)：

CSB-EP009369HU(A4)
說(shuō)明書：

MSDS Datasheet
規(guī)格：

￥1536
圖片：
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

純度：

Greater than 90% as determined by SDS-PAGE.
基因名：

GFAP
Uniprot No.：

P14136
種屬：

Homo sapiens (Human)
蛋白長(zhǎng)度：

Partial
來(lái)源：

E.coli
分子量：

20.6 kDa
表達(dá)區(qū)域：

292-432aa
氨基酸序列

LTCDLESLRGTNESLERQMREQEERHVREAASYQEALARLEEEGQSLKDEMARHLQEYQDLLNVKLALDIEIATYRKLLEGEENRITIPVQTFSNLQIRETSLDTKSVSEGHLKRNIVVKTVEMRDGEVIKESKQEHKDVM
Note: The complete sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application, please explicitly request the full and complete sequence of this protein before ordering.
蛋白標(biāo)簽：

N-terminal 6xHis-tagged
產(chǎn)品提供形式：

Liquid or Lyophilized powder Warning: in_array() expects parameter 2 to be array, null given in /www/web/cusabio_cn/public_html/caches/caches_template/default/content/show_product_protein.php on line 662
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
緩沖液：

If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose.
復(fù)溶：

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
儲(chǔ)存條件：

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
保質(zhì)期：

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
貨期：

3-7 business days
注意事項(xiàng)：

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA：

Please contact us to get it.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells.
基因功能參考文獻(xiàn)：
1. The features of the neuropathology and immunopathology of GFAP astrocytopathies were perivascular inflammation and loss of astrocytes and neurons PMID: 29193473
2. amniotic fluid -GFAP levels differentiate between myelomeningocele and myeloschisis, and raise interesting questions regarding the clinical significance between the 2 types of defects. PMID: 28768252
3. Desmin, Glial Fibrillary Acidic Protein, Vimentin, and Peripherin are type III intermediate filaments that have roles in health and disease [review] PMID: 29196434
4. Plasma concentration of GFAP demonstrated associations with stroke occurrence in a West African cohort but was not associated with stroke severity or mortality. PMID: 29074065
5. This study demonstrated that Concentrations of microparticles expressing GFAP and AQP4 were significantly higher in the traumatic brain injury group compared with healthy controls. PMID: 28972406
6. The authors observed higher serum levels of GFAP and UCH-L1 in brain-injured children compared with controls and also demonstrated a step-wise increase of biomarker concentrations over the continuum of severity from mild to severe traumatic brain injury. Serum UCH-L1 and GFAP concentrations also strongly predicted poor outcome. PMID: 27319802
7. Study examined if QKI6B expression can predict the outcome of GFAP, and several oligodendrocyte-related genes, in the prefrontal cortex of brain samples of schizophrenic individuals. QKI6B significantly predicts the expression of GFAP, but does not predict oligodendrocyte-related gene outcome, as previously seen with other QKI isoforms. PMID: 28552414
8. GFAP, along with tau and AmyloidBeta42, were increased in plasma up to 90 days after traumatic brain injury compared with controls. PMID: 27312416
9. Results show that the positive rates and expression levels of nestin, tyrosine hydroxylase (TH), GFAP and IL-17 were significantly decreased while Foxp3 and the ratio of Foxp3/IL-17 were statistically elevated in BM of AML patients. PMID: 27016413
10. GFAP levels >0.29 ng/ml were seen only in intracerebral hemorrhage, thus confirming the diagnosis of ICH during prehospital care. PMID: 27951536
11. These results indicate that autoantibodies against GFAP could serve as a predictive marker for the development of overt autoimmune diabetes. PMID: 28546444
12. Higher median plasma GFAP values were documented in intracerebral hemorrhage compared with acute ischemic stroke, stroke mimics, and controls. PMID: 28751552
13. GFAP is specifically expressed in the auricular chondrocytes, and assumes a pivotal role in resistance against mechanical stress. PMID: 28063220
14. Bevacizumab treatment was also associated with structural protein abnormalities, with decreased GFAP and vimentin content and upregulated GFAP and vimentin mRNA expression. PMID: 28419863
15. the exchange of GFP-GFAPdelta was significantly slower than the exchange of GFP-GFAPalpha with the intermediate filament-network. PMID: 27141937
16. Tat expression or GFAP expression led to formation of GFAP aggregates and induction of unfolded protein response (UPR) and endoplasmic reticulum (ER) stress in astrocytes. PMID: 27609520
17. This study demonstrated that GFAP exhibited distinct temporal profiles over the course of 7 days in patient with traumatic brain injury. PMID: 27018834
18. e data indicates that serum GFAP levels may be associated with severity of autism spectrum disorders among Chinese children. PMID: 28088366
19. High GFAP expression is associated with retinoblastoma. PMID: 27488116
20. Overall, glial fibrillary acidic protein reflected no evidence for significant peripartum brain injury in neonates with congenital heart defects, but there was a trend for elevation by postnatal day 4 in neonates with left heart obstruction. PMID: 26786018
21. serum levels of GFAP were significantly lower in autism spectrum disorders than controls PMID: 27097671
22. We found downregulation of GFAP mRNA and protein in the mediodorsal thalamus and caudate nucleus of depressed suicides compared with controls, whereas GFAP expression in other brain regions was similar between groups. Furthermore, a regional comparison including all samples revealed that GFAP expression in both subcortical regions was, on average, between 11- and 15-fold greater than in cerebellum and neocortex. PMID: 26033239
23. No difference in cord blood concentration found between hypoxic-ischemic encephalopathy neonates and controls PMID: 26135781
24. GFAP is upregulated following an insult or injury to the brain, additionally making it an indicator of CNS pathology. PMID: 25846779
25. This study demonistrated that the density of GFAP-immunoreactive astrocytes is decreased in left hippocampi in major depressive disorder PMID: 26742791
26. This study demonstrated that GFAP as a promising biomarker to distinguish ischemic stroke from intracerebral hemorrhage. PMID: 26526443
27. The levels of GFAP in Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration patients were significantly higher than those in the healthy control subjects. PMID: 26485083
28. GFAP is significantly associated with outcome, but it does not add predictive power to commonly used prognostic variables in a population of patients with TBI of varying severities. PMID: 26547005
29. Neither duplications nor deletions of GFAP were found, suggesting that GFAP coding-region rearrangements may not be involved in Alexander disease or Alexanderrelated leukoencephalopathies. PMID: 26208460
30. The data suggest that human vitreous body GFAP is a protein biomarker for glial activation in response to retinal pathologies. PMID: 26279003
31. Studied diagnostic Value of Serum Levels of GFAP, pNF-H, and NSE Compared With Clinical Findings in Severity Assessment of Human Traumatic Spinal Cord Injury. PMID: 25341992
32. GFAP peaks early during haemorrhagic brain lesions (at significantly higher levels), and late in ischaemic events, whereas antibodies against NR2 RNMDA have significantly higher levels during ischemic stroke at all time-points. PMID: 26081945
33. There was an absence of GFAP in astrocytes during early fetal spinal cord development until 9 months of gestation , and the appearance of GFAP-positive reactivity was later than that of neurons. PMID: 25904356
34. It could be a clinically relevant marker associated with tumor invasiveness in cerebral astrocytomas. PMID: 25178519
35. These data imply that a tight regulation of histone acetylation in astrocytes is essential, because dysregulation of gene expression causes the aggregation of GFAP, a hallmark of human diseases like Alexander's disease. PMID: 25128567
36. Identification of a novel nonsense mutation in the rod domain of GFAP that is associated with Alexander disease. PMID: 24755947
37. The role of S100B protein, neuron-specific enolase, and glial fibrillary acidic protein in the evaluation of hypoxic brain injury in acute carbon monoxide poisoning PMID: 24505052
38. GFAP, the principal intermediate filament protein of astrocytes, is involved in physiological, but in particular, in pathophysiological functions of astrocytes, the latter ones being connected with astrocyte activation and reactive gliosis. [Review] PMID: 25726916
39. The data on the changes in expression of GFAP in Alexander disease caused by the primary pathology of astrocytes are presented. PMID: 25859599
40. A combined profile of preoperative IGFBP-2, GFAP, and YKL-40 plasma levels could serve as an additional diagnostic tool for patients with inoperable brain lesions suggestive of Glioblastoma multiforme. PMID: 25139333
41. There are significant increases in glial fibrillary acidic protein levels in children undergoing cardiopulmonary bypass for repair of congenital heart disease. The highest values were seen during the re-warming phase. PMID: 23845562
42. This stuidy demonistrated that Fibrillary astrocytes are decreased in the subgenual cingulate in schizophrenia. PMID: 24374936
43. TBI patients showed an average 3.77 fold increase in anti-GFAP autoantibody levels from early (0-1 days) to late (7-10 days) times post injury. PMID: 24667434
44. We showed that GFAP is over-expressed and hypophosphorylated in the enteric glial cells of Parkinson's disease patients as compared to healthy subjects PMID: 24749759
45. Its expression is associated with plaque load related astrogliosis in Alzheimer's disease. PMID: 24269023
46. The findings of this study that caspase-mediated GFAP proteolysis may be a common event in the context of both the GFAP mutation and excess. PMID: 24102621
47. This study demonistratedt hat Increased expression of glial fibrillary acidic protein in prefrontal cortex in psychotic illness PMID: 23911257
48. Data indicate that Gfapdelta is expressed in the in developing mouse brain sub-ventricular zones in accordance with the described localization in the developing and adult human brain. PMID: 23991052
49. GFAP-breakdown products blood levels reliably distinguished severity of injury in traumatic brain injury patients. PMID: 23489259
50. The C/C genotype at rs2070935 of the GFAP promoter in late-onset AxD was associated with an earlier onset and a more rapid progression of ambulatory disability compared with the other genotypes. PMID: 23903069
顯示更多

收起更多
相關(guān)疾病：

Alexander disease (ALXDRD)
亞細(xì)胞定位：

Cytoplasm.
蛋白家族：

Intermediate filament family
組織特異性：

Expressed in cells lacking fibronectin.
數(shù)據(jù)庫(kù)鏈接：

HGNC: 4235

OMIM: 137780

KEGG: hsa:2670

STRING: 9606.ENSP00000253408

UniGene: Hs.514227